Galectin Therapeutics (GALT) Short-Term Debt issuances (2022 - 2026)

Galectin Therapeutics' Short-Term Debt issuances history runs 5 years deep, the most recent figure standing at $257000.0 for Q1 2026.

• In Q1 2026, Short-Term Debt issuances changed N/A year-over-year to $257000.0; the TTM figure through Mar 2026 stood at $10.3 million (down 48.72% YoY), while the FY2025 annual figure was $21.0 million, down 30.0% from the prior year.
• Short-Term Debt issuances for Q1 2026 stood at $257000.0, down from $10.0 million in the prior quarter.
• The five-year high for Short-Term Debt issuances was $10.0 million in Q4 2022, with the low at $257000.0 in Q1 2026.
• The 5-year median for Short-Term Debt issuances is $10.0 million (2022), against an average of $8.5 million.
• The sharpest annual moves came in 2023 and 2025: Short-Term Debt issuances changed 0.0% in 2023, then plunged 50.0% in 2025.
• Galectin Therapeutics' Short-Term Debt issuances stood at $10.0 million in 2022, then changed by 0.0% to $10.0 million in 2023, then changed by 0.0% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025, then plunged by 97.43% to $257000.0 in 2026.
• Business Quant data shows GALT's Short-Term Debt issuances at $257000.0 in Q1 2026, $10.0 million in Q4 2025, and $5.0 million in Q2 2025.